+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Actinic Keratosis Treatment Market by Drug Type, Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5019892
  • Report
  • February 2020
  • Region: Global
  • 235 pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • 3M Company
  • Almirall S.A.
  • Biofrontera Inc.
  • Hill Dermaceuticals Inc.
  • LEO Pharma A/S
  • Mylan N.V.
The global actinic keratosis treatment market was valued at $1,117 million in 2018, and is projected to reach $1,558 million by 2026, registering a CAGR of 4.2% from 2019 to 2026. Actinic keratosis (AK) is the most common precancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun or indoor tanning characterized by rough, scaly patch on skin. It is most commonly found on face, lips, ears, back of your hands, forearms, scalp, or neck. Different types of treatment options available for the treatment of actinic keratosis include cryotherapy, photodynamic therapy, topical medications, and combination therapy. Drugs such as fluorouracil, imiquimod, diclofenac, ingenol mebutate, and others have been approved for the treatment of actinic keratosis.



Significant increase in prevalence of actinic keratosis, use of topical therapeutics as a first line treatment option, rise in demand for actinic keratosis therapeutics, strong presence of pipeline drugs, and rise in geriatric population are the key factors that fuel the growth of the actinic keratosis treatment market. Moreover, rise in adoption of actinic keratosis treatment medications, increase in R&D for the innovation of new products, and surge in healthcare awareness toward actinic keratosis treatment are other factors that contribute toward the growth of the market. However, availability of alternate therapies for treatment of actinic keratosis can hamper the market growth.

The actinic keratosis treatment market is segmented on the basis of drug type, type, distribution channel, and region. By drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. On the basis of type, the market is bifurcated into prescription and OTC. According to distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Drug Type
  • Fluorouracil
  • Imiquimod
  • Diclofenac
  • Others
By Type
  • Prescription
  • OTC
Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • 3M Company
  • Almirall, S.A.
  • Bausch Health Companies Inc.
  • Biofrontera, Inc.
  • Hill Dermaceuticals, Inc.
  • LEO Pharma A/S
  • Mylan N.V
  • Novartis AG
  • Stanford Chemicals
  • Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Nestlé S.A.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Company
  • Almirall S.A.
  • Biofrontera Inc.
  • Hill Dermaceuticals Inc.
  • LEO Pharma A/S
  • Mylan N.V.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of actinic keratosis
3.4.1.2. Potential drugs present in pipeline
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraint
3.4.2.1. Availability of alternate treatment options
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis

CHAPTER 4: ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Fluorouracil
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Imiquimod
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Diclofenac
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

CHAPTER 5: ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. OTC
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online providers
6.4.1. Market size and forecast
6.4.2. Market analysis, by country

CHAPTER 7: ACTINIC KERATOSIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. actinic keratosis treatment market, by drug type
7.2.2.1.2. U.S. actinic keratosis treatment market, by type
7.2.2.1.3. U.S. actinic keratosis treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada actinic keratosis treatment market, by drug type
7.2.2.2.2. Canada actinic keratosis treatment market, by type
7.2.2.2.3. Canada actinic keratosis treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico actinic keratosis treatment market, by drug type
7.2.2.3.2. Mexico actinic keratosis treatment market, by type
7.2.2.3.3. Mexico actinic keratosis treatment market, by distribution channel
7.2.3. North America market size and forecast, by drug type
7.2.4. North America actinic keratosis treatment market, by type
7.2.5. North America actinic keratosis treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany actinic keratosis treatment market, by drug type
7.3.2.1.2. Germany actinic keratosis treatment market, by type
7.3.2.1.3. Germany actinic keratosis treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France actinic keratosis treatment market, by drug type
7.3.2.2.2. France actinic keratosis treatment market, by type
7.3.2.2.3. France actinic keratosis treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK actinic keratosis treatment market, by drug type
7.3.2.3.2. UK actinic keratosis treatment market, by type
7.3.2.3.3. UK actinic keratosis treatment market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy actinic keratosis treatment market, by drug type
7.3.2.4.2. Italy actinic keratosis treatment market, by type
7.3.2.4.3. Italy actinic keratosis treatment market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain actinic keratosis treatment market, by drug type
7.3.2.5.2. Spain actinic keratosis treatment market, by type
7.3.2.5.3. Spain actinic keratosis treatment market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe actinic keratosis treatment market, by drug type
7.3.2.6.2. Rest of Europe actinic keratosis treatment market, by type
7.3.2.6.3. Rest of Europe actinic keratosis treatment market, by distribution channel
7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe actinic keratosis treatment market, by type
7.3.5. Europe actinic keratosis treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan actinic keratosis treatment market, by drug type
7.4.2.1.2. Japan actinic keratosis treatment market, by type
7.4.2.1.3. Japan actinic keratosis treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China actinic keratosis treatment market, by drug type
7.4.2.2.2. China actinic keratosis treatment market, by type
7.4.2.2.3. China actinic keratosis treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia actinic keratosis treatment market, by drug type
7.4.2.3.2. Australia actinic keratosis treatment market, by type
7.4.2.3.3. Australia actinic keratosis treatment market, by distribution channel
7.4.2.4. Rest of Asia-Pacific
7.4.2.4.1. Rest of Asia-Pacific actinic keratosis treatment market, by drug type
7.4.2.4.2. Rest of Asia-Pacific actinic keratosis treatment market, by type
7.4.2.4.3. Rest of Asia-Pacific actinic keratosis treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific actinic keratosis treatment market, by type
7.4.5. Asia-Pacific actinic keratosis treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil actinic keratosis treatment market, by drug type
7.5.2.1.2. Brazil actinic keratosis treatment market, by type
7.5.2.1.3. Brazil actinic keratosis treatment market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia actinic keratosis treatment market, by drug type
7.5.2.2.2. Saudi Arabia actinic keratosis treatment market, by type
7.5.2.2.3. Saudi Arabia actinic keratosis treatment market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa actinic keratosis treatment market, by drug type
7.5.2.3.2. South Africa actinic keratosis treatment market, by type
7.5.2.3.3. South Africa actinic keratosis treatment market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA actinic keratosis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA actinic keratosis treatment market, by type
7.5.2.4.3. Rest of LAMEA actinic keratosis treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA actinic keratosis treatment market, by type
7.5.5. LAMEA actinic keratosis treatment market, by distribution channel

CHAPTER 8: COMPANY PROFILES
8.1. 3M Company
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Almirall, S.A.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Bausch Health Companies Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Biofrontera, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Hill Dermaceuticals, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. LEO Pharma A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Mylan N.V
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Stanford Chemicals
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Company
  • Almirall S.A.
  • Biofrontera Inc.
  • Hill Dermaceuticals Inc.
  • LEO Pharma A/S
  • Mylan N.V.
According to the report titled 'Actinic Keratosis Treatment Market by Drug Type, Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global actinic keratosis treatment market size was valued at $1,117million in 2018, and is projected to reach $1,558 million by 2026, growing at a CAGR of 4.2% from 2019 to 2026.

Actinic keratosis (AK) is the most common precancer that forms on skin damaged by long-term exposure to ultraviolet radiation from the sun and/or indoor tanning. It is characterized by rough, scaly patch on skin most commonly found on your face, lips, ears, back of your hands, forearms, scalp, or neck. Surgical procedures, topical treatments, photodynamic therapy, and combination therapy are used for treatment of actinic keratosis. Drugs such as 5-fluorouracil, diclofenac, imiquimod, and ingenol mebutate have been approved for the treatment of actinic keratosis.

The major factors that boost the growth of the global actinic keratosis treatment market include rise in prevalence of actinic keratosis, grow thin geriatric population, increase in demand for actinic keratosis drugs, preferable usage of topical actinic keratosis therapeutics, and increase in healthcare awareness toward a clinic keratosis treatment. In addition, surge in clinical R&D of new drugs for the treatment of actinic keratosis globe are further expected to boost the market growth during the forecast period. However, availability of alternate treatment are expected to hamper the market growth.

Based on drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. Presently fluorouracil dominates the global market, and is anticipated to continue this trend during the forecast period. The key factors that drive the market growth are use of fluorouracil as a first line treatment, increase in demand & cost effectivity, and wide availability of fluorouracil act as the key factors that significantly contribute toward the growth of the market.

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.

According to Onkar Sumant, Manager, Healthcare, “The growth of the actinic keratosis treatment market is attributed to rise in prevalence of actinic keratosis across the globe. Furthermore, rise in adoption of topical therapeutics as a first line treatment and increase in number of pipeline drugs for the actinic keratosis treatment are the other factors that contribute to the growth of the market.”

KEY FINDINGS OF THE STUDY
  • Depending on drug type, the fluorouracil segment held more than one third share in the global market in 2018.
  • By type, the prescription segment accounted for the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
  • Based on distribution channel, the drug stores & retail pharmacies segment held approximately half share in the global market in 2018.
  • Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period.
In 2018, North America accounted for the major share in the actinic keratosis treatment market, and is expected to continue this trend during the forecast period, owing to availability of higher number of target population, higher number of R&D activities with large presence of key players, rise in demand for actinic keratosis treatment drugs, and higher healthcare awareness. However, Asia-Pacific is expected to register the highest growth in the future, owing to rise in prevalence of actinic keratosis in countries such as Australia & New Zealand, and the developing R&D sector are influencing the market growth.
Note: Product cover images may vary from those shown
  • 3M Company
  • Almirall S.A.
  • Bausch Health Companies Inc.
  • Biofrontera Inc.
  • Hill Dermaceuticals Inc.
  • LEO Pharma A/S
  • Mylan N.V.
  • Novartis AG
  • Stanford Chemicals
  • Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals Inc.).
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll